

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal617srh

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 3 Feb 06 Engineering Information Encompass files have new names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7 May 07 DGENE Reload

NEWS EXPRESS April 18 CURRENT WINDOWS VERSION IS V6.0,
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
AND CURRENT DISCOVER FILE IS DATED 04/06

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:55:14 ON 17 MAY 2001

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.15	0.15

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 10:55:46 ON 17 MAY 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 16 MAY 2001 HIGHEST RN 336099-02-6

DICTIONARY FILE UPDATES: 16 MAY 2001 HIGHEST RN 336099-02-6

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
for details.

=> BPD-MA/cn

BPD-MA IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s BPD-MA/cn

L1 1 BPD-MA/CN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS

RN 129497-78-5 REGISTRY

CN 23H,25H-Benzo[b]porphine-9,13-dipropionic acid, 18-ethenyl-4,4a-dihydro-
3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester,
(4R,4aS)-rel- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 23H,25H-Benzo[b]porphine-9,13-dipropionic acid, 18-ethenyl-4,4a-dihydro-
3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester,
trans-

OTHER NAMES:

CN (.+-.)-trans-3,4-Dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-
23H,25H-benzo[b]porphine-9,13-dipropionic acid, 3,4,9-trimethyl ester
mixt. with

(.+-.)-trans-3,4-dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-
18-vinyl-23H,25H-benzo[b]porphine-9,13-dipropionic acid, 3,4,13-trimethyl
ester

CN **BPD-MA**

CN CL 318952

CN Verteporfin

FS STEREOSEARCH

DR 121987-00-6, 129162-83-0, 136415-38-8

MF C41 H42 N4 O8

CI IDS

SR CA

LC STN Files: ADISINSIGHT, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAPLUS,
CEN,

CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, MEDLINE,
MRCK*, PHAR, PROMT, TOXLINE, TOXLIT, USAN, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO


CM 1

CRN 121310-58-5

CMF C40 H40 N4 O8

Relative stereochemistry.

Double bond geometry unknown.



CM 2

CRN 67-56-1

CMF C H4 O

H₃C-OH

145 REFERENCES IN FILE CA (1967 TO DATE)
 7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 146 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s A-EA6/cn
 L2 0 A-EA6/CN

=> fil stng		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	12.51	12.66

FILE 'STNGUIDE' ENTERED AT 11:02:22 ON 17 MAY 2001
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
 AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: May 11, 2001 (20010511/UP).

=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.00	12.66

FILE 'REGISTRY' ENTERED AT 11:10:12 ON 17 MAY 2001
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 16 MAY 2001 HIGHEST RN 336099-02-6
DICTIONARY FILE UPDATES: 16 MAY 2001 HIGHEST RN 336099-02-6

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
for details.

=> s porphyrin/cn
L3 1 PORPHYRIN/CN

=> s porphyrin
2983 PORPHYRIN
2 PORPHYRINS
L4 2983 PORPHYRIN
(PORPHYRIN OR PORPHYRINS)

=> s porfimer/cn
L5 0 PORFIMER/CN

=> s porfimer
L6 1 PORFIMER

=> d

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN 87806-31-3 REGISTRY
CN **Photofrin Porfimer sodium (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN CL 184116
CN DHE
CN Photofrin 2
CN Photofrin II
CN **Porfimer sodium**
CN PPS
MF Unspecified
CI MAN
LC STN Files: ADISINSIGHT, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, CA,
CAPLUS, CBNB, CEN, CIN, CSNB, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU,
DRUGUPDATES, IPA, MRCK*, PHAR, PROMT, RTECS*, TOXLINE, TOXLIT, USAN,
USPATFULL
(*File contains numerically searchable property data)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
466 REFERENCES IN FILE CA (1967 TO DATE)
15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
466 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> fil stng		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	17.32	29.98

FILE 'STNGUIDE' ENTERED AT 11:11:26 ON 17 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: May 11, 2001 (20010511/UP).

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	29.98

FULL ESTIMATED COST

INDEX 'ADISALERTS, ADISINSIGHT, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, ...' ENTERED AT 11:15:02 ON 17 MAY 2001

59 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s 11 or (L 318952) or Verteporfin

- 11* FILE ADISALERTS
- 3 FILE ADISINSIGHT
- 0* FILE AQUASCI
- 3 FILE BIOBUSINESS
- 3* FILE BIOCOMMERCE
- 76 FILE BIOSIS

10 FILES SEARCHED...

- 8 FILE BIOTECHNO
- 1* FILE CABA
- 132 FILE CANCERLIT
- 66* FILE CAPLUS
- 1* FILE CEABA-VTB
- 1 FILE CEN
- 32 FILE CIN
- 1* FILE CONFSCI
- 0* FILE CROPB
- 0* FILE CROPU

20 FILES SEARCHED...

- 0* FILE DDFB
- 36* FILE DDFU
- 0* FILE DGENE
- 0* FILE DRUGB
- 13 FILE DRUGLAUNCH
- 9 FILE DRUGMONOG2
- 39 FILE DRUGNL
- 36* FILE DRUGU
- 1 FILE DRUGUPDATES
- 4* FILE EMBAL
- 70 FILE EMBASE
- 23* FILE ESBIODBASE
- 0* FILE FOMAD
- 0* FILE FOREGE
- 0* FILE FROSTI
- 0* FILE GENBANK
- 0* FILE HEALSAFE
- 0* FILE IFIPAT
- 0* FILE KOSMET

9* FILE LIFESCI
 0* FILE MEDICONF
 148 FILE MEDLINE
 44 FILES SEARCHED...
 0* FILE NTIS
 0* FILE OCEAN
 43* FILE PASCAL
 1 FILE PHAR
 5* FILE PHIC
 79* FILE PHIN
 196 FILE PROMT
 85* FILE SCISEARCH
 32 FILE TOXLINE
 38 FILE TOXLIT
 11* FILE USPATFULL
 2 FILE WPIDS
 2 FILE WPINDEX

35 FILES HAVE ONE OR MORE ANSWERS, 59 FILES SEARCHED IN STNINDEX

L7 QUE L1 OR (L 318952) OR VERTEPORFIN

=> s restenos? or restrict? or (intimal hyperplas?) or narrow?

5038 FILE ADISALERTS
 344 FILE ADISINSIGHT
 24271 FILE AGRICOLA
 2216 FILE ANABSTR
 19791 FILE AQUASCI
 12390 FILE BIOBUSINESS
 997 FILE BIOCOMMERCE
 231140 FILE BIOSIS
 12776 FILE BIOTECHABS
 12776 FILE BIOTECHDS
 79618 FILE BIOTECHNO
 80189 FILE CABA
 45805 FILE CANCERLIT
 288989 FILE CAPLUS
 4253 FILE CEABA-VTB
 1598 FILE CEN
 9004 FILE CIN
 4076 FILE CONFSCI
 512 FILE CROPB
 2079 FILE CROPU

20 FILES SEARCHED...
 1081 FILE DDFB
 6537 FILE DDFU
 60159 FILE DGENE
 1081 FILE DRUGB
 426 FILE DRUGLAUNCH
 2 FILE DRUGMONOG2
 362 FILE DRUGNL
 13072 FILE DRUGU
 287 FILE DRUGUPDATES
 1943 FILE EMBAL
 192382 FILE EMBASE
 63621 FILE ESBIODBASE
 244 FILE FOMAD
 698 FILE FOREGE
 3119 FILE FROSTI
 6524 FILE FSTA

195972 FILE GENBANK
 2064 FILE HEALSAFE
 136591 FILE IFIPAT
 39 FILES SEARCHED...
 38964 FILE JICST-EPLUS
 299 FILE KOSMET
 76071 FILE LIFESCI
 149 FILE MEDICONF
 228280 FILE MEDLINE
 3305 FILE NIOSHTIC
 34472 FILE NTIS
 7498 FILE OCEAN
 124528 FILE PASCAL
 262 FILE PHAR
 81 FILE PHIC
 12271 FILE PHIN
 228071 FILE PROMT
 229359 FILE SQISEARCH
 15 FILE SYNTHLINE
 37856 FILE TOXLINE
 53346 FILE TOXLIT
 56 FILES SEARCHED...
 762478 FILE USPATFULL
 180497 FILE WPIDS
 180497 FILE WPINDEX

59 FILES HAVE ONE OR MORE ANSWERS, 59 FILES SEARCHED IN STNINDEX

L8 QUE RESTENOS? OR RESTRICT? OR (INTIMAL HYPERPLAS?) OR NARROW?

=> s 17 and 18

0* FILE ADISALERTS
 1 FILE ADISINSIGHT
 0* FILE AQUASCI
 0* FILE BIOCOMMERCE
 0* FILE CABA
 4 FILE CANCERLIT
 5* FILE CAPLUS
 0* FILE CEABA-VTB
 0* FILE CONFSCI
 0* FILE CROPB
 0* FILE CROPU
 0* FILE DDFB
 1* FILE DDFU
 0* FILE DGENE
 0* FILE DRUGB
 26 FILES SEARCHED...
 1 FILE DRUGNL
 1* FILE DRUGU
 1 FILE DRUGUPDATES
 0* FILE EMBAL
 3 FILE EMBASE
 0* FILE ESBIODASE
 0* FILE FOMAD
 0* FILE FOREGE
 0* FILE FROSTI
 0* FILE GENBANK
 0* FILE HEALSAFE
 0* FILE IFIPAT
 0* FILE KOSMET

0* FILE LIFESCI
 0* FILE MEDICONF
 7 FILE MEDLINE
 0* FILE NTIS
 0* FILE OCEAN
 1* FILE PASCAL
 48 FILES SEARCHED...
 1 FILE PHAR
 0* FILE PHIC
 5* FILE PHIN
 5 FILE PROMT
 2* FILE SCISEARCH
 2 FILE TOXLINE
 9* FILE USPATFULL
 1 FILE WPIDS
 1 FILE WPINDEX

18 FILES HAVE ONE OR MORE ANSWERS, 59 FILES SEARCHED IN STNINDEX

L9 QUE L7 AND L8

=> d rank

F1 9* USPATFULL
 F2 7 MEDLINE
 F3 5 PROMT
 F4 5* CAPLUS
 F5 5* PHIN
 F6 4 CANCERLIT
 F7 3 EMBASE
 F8 2 TOXLINE
 F9 2* SCISEARCH
 F10 1 ADISINSIGHT
 F11 1 DRUGNL
 F12 1 DRUGUPDATES
 F13 1 PHAR
 F14 1 WPIDS
 F15 1 WPINDEX
 F16 1* DDFU
 F17 1* DRUGU
 F18 1* PASCAL

=> file f1-f18

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
6.75	36.73

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 11:23:49 ON 17 MAY 2001
 CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 11:23:49 ON 17 MAY 2001

FILE 'PROMT' ENTERED AT 11:23:49 ON 17 MAY 2001
 COPYRIGHT (C) 2001 Gale Group. All rights reserved.

FILE 'CAPLUS' ENTERED AT 11:23:49 ON 17 MAY 2001
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PHIN' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 PJB Publications Ltd. (PJB)

FILE 'CANCERLIT' ENTERED AT 11:23:49 ON 17 MAY 2001

FILE 'EMBASE' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'TOXLINE' ENTERED AT 11:23:49 ON 17 MAY 2001

FILE 'SCISEARCH' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 Institute for Scientific Information (ISI) (R)

FILE 'ADISINSIGHT' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 Adis International Ltd. (ADIS)

FILE 'DRUGNL' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 IMSWORLD Publications Ltd

FILE 'DRUGUPDATES' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 IMSWORLD Publications Ltd

FILE 'PHAR' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 PJB Publications Ltd. (PJB)

FILE 'WPIDS' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DRUGU' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'PASCAL' ENTERED AT 11:23:49 ON 17 MAY 2001
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2001 INIST-CNRS. All rights reserved.

=> s 19
7 FILES SEARCHED...
'CN' IS NOT A VALID FIELD CODE
14 FILES SEARCHED...
'CN' IS NOT A VALID FIELD CODE
L10 51 L9

=> dup rem l10
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, DRUGUPDATES, PHAR'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L10
L11 45 DUP REM L10 (6 DUPLICATES REMOVED)

=> d ibib abs 1-10

L11 ANSWER 1 OF 45 PHIN COPYRIGHT 2001 PJB

ACCESSION NUMBER: 2001:3608 PHIN
DOCUMENT NUMBER: C00696126

DATA ENTRY DATE: 15 Jan 2001
TITLE: Breakthrough products enter the US market
SOURCE: Clinica (2001) No. 941 Review-Issue 2000 p33
DOCUMENT TYPE: Newsletter
FILE SEGMENT: FULL

L11 ANSWER 2 OF 45 USPATFULL

ACCESSION NUMBER: 2001:21079 USPATFULL

TITLE: Scanning laser ophthalmoscope for selective
therapeutic laser

INVENTOR(S): Van de Velde, Frans J., Boston, MA, United States

PATENT ASSIGNEE(S): Van de Velde, Jozek F., Oosterzele, Belgium (non-U.S.
individual)

	NUMBER	DATE
PATENT INFORMATION:	US 6186628	20010213
APPLICATION INFO.:	US 1999-431680	19991101 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-317098, filed on 23 May 1999, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Manuel, George	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	631	

AB A combination of a scanning laser ophthalmoscope and external laser
sources (52) is used for microphotocoagulation and photodynamic
therapy,
two examples of selective therapeutic laser. A linkage device
incorporating a beamsplitter (56) and collimator-telescope (60) is
adjusted to align the pivot point (16) of the scanning lasers (38, 40)
and external laser source (52). A similar pivot point minimizes
wavefront aberrations, enables precise focusing and registration of the
therapeutic laser beam (52) on the retina without the risk of
vignetting. One confocal detection pathway of the scanning laser
ophthalmoscope images the retina. A second and synchronized detection
pathway with a different barrier filter (48) is needed to draw the
position and extent of the therapeutic laser spot on the retinal image,
as an overlay (64). Advanced spatial modulation increases the
selectivity of the therapeutic laser. In microphotocoagulation, an
adaptive optics lens (318) is attached to the scanning laser
ophthalmoscope, in proximity of the eye. It corrects the higher order
optical aberrations of the eye optics, resulting in smaller and better
focused applications. In photodynamic therapy, a spatial modulator
(420)
is placed within the collimator-telescope (60) of the therapeutic laser
beam (52), customizing its shape as needed. A similar effect can be
obtained by modulating a scanning laser source (38) of appropriate
wavelength for photodynamic therapy.

L11 ANSWER 3 OF 45 USPATFULL

ACCESSION NUMBER: 2001:14260 USPATFULL

TITLE: Method for inhibiting apoptosis induced by
photodynamic

INVENTOR(S): therapy using a cysteine or serine protease inhibitor
Granville, David J., Vancouver, Canada
Levy, Julia G., Vancouver, Canada

PATENT ASSIGNEE(S): Hunt, David W. C., Vancouver, Canada
QLT Inc., Victoria, Canada (non-U.S. corporation)
University of British Columbia, Vancouver, Canada
(non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6180402	20010130
APPLICATION INFO.:	US 1996-754491	19961120 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Saucier, Sandra E.	
LEGAL REPRESENTATIVE:	Morrison & Foerster, LLP	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	1095	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition and method for inhibiting apoptosis, or decreasing the rate or extent of apoptosis, in target cells. The method comprises the step of the step of contacting the target cells with an apoptosis-regulating amount of at least one cysteine or serine protease inhibitor that:

a. inhibits the conversion of the pro-enzyme form of CPP32 to its enzymatically-active form;

b. blocks the proteolytic action of activated CPP32 against its cellular substrates; or

c. both.

The method is particularly applicable to ameliorating the side effects of, or enhancing the selectivity, of photodynamic therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 45 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:265274 CAPLUS
DOCUMENT NUMBER: 134:262933
TITLE: Significance of dosimetry in photodynamic therapy of injured arteries
INVENTOR(S): Lamuraglia, Glenn Michael
PATENT ASSIGNEE(S): The General Hospital Corporation Doing Business as Massachusetts General Hos, USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001024825	A2	20010412	WO 2000-US27140	20001002
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1999-157325	P 19991001
			US 1999-157409	P 19991001

AB Photodynamic therapy (PDT), the light activation of methylene blue or benzoporphyrin derivs. to produce free-radicals, was shown in vivo to inhibit **intimal hyperplasia** (IH) and **restenosis**. An effective amt. of photosensitizer is delivered to the injured site in vivo and the site is irradiated with sufficient light energy between about 300 and 900 nm such that **restenosis** is modulated. The light source used is a laser and the light energy about 100 J/cm². The present invention provides an effective clin. approach for PDT treatment which modulates the vascular intervention injury healing response.

L11 ANSWER 5 OF 45 PROMT COPYRIGHT 2001 Gale Group

ACCESSION NUMBER: 2001:103819 PROMT
TITLE: Letter to the Editor.(request for age-related macular degeneration percentages)(Brief Article)(Letter to the Editor)
AUTHOR(S): Sonnier, William, Jr.
SOURCE: Ophthalmology Times, (1 Aug 2000) Vol. 25, No. 15, pp. 3.
ISSN: 0193-032X.
PUBLISHER: Advanstar Communications, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 159
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB Reader questions AMD percentages
THIS IS THE FULL TEXT: COPYRIGHT 2000 Advanstar Communications, Inc.

Subscription: \$150.00 per year. Published semimonthly. 7500 Old Oak Blvd.,
Cleveland, OH 44130.

L11 ANSWER 6 OF 45 PROMT COPYRIGHT 2001 Gale Group

ACCESSION NUMBER: 2000:468002 PROMT
TITLE: OTHER NEWS TO NOTE.
SOURCE: BIOWORLD Today, (2 Jun 2000) Vol. 11, No. 107.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1701
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB Abbott Laboratories, of Abbott Park, Ill., said it submitted a new drug application to market ABT-378/r (lopinavir/ritonavir), its investigational

antiretroviral therapy for HIV and AIDS. The company is seeking accelerated approval based on ongoing Phase II/III studies. The regulatory submission in Europe is planned for late June and applications for other markets outside the U.S. will follow throughout the year. Separately, Abbott has sued Boston's Children's Hospital and one of its cancer researchers, Judah Folkman, alleging they falsely took credit for a medical development in treating malignant tumors by telling U.S. patent reviewers about the discovery of tumor-inhibiting properties of a small section of an angiostatin protein known as Kringle 5. According to wire reports, Abbott filed suit in U.S. District Court in Boston and says one of its scientists, Donald Davidson, actually discovered the properties, making Abbott the rightful owner of the patent.

THIS IS THE FULL TEXT: COPYRIGHT 2000 American Health Consultants, Inc.

Subscription: \$1350.00 per year. Published daily (5 times a week).

L11 ANSWER 7 OF 45 PHIN COPYRIGHT 2001 PJB

ACCESSION NUMBER: 2000:5549 PHIN
DOCUMENT NUMBER: S00656918
DATA ENTRY DATE: 16 Feb 2000
TITLE: Preventive products reap most rewards it could easily
become the world's best-selling drug.
SOURCE: Scrip (2000) No. 2514 Review-Issue 1999 p65
DOCUMENT TYPE: Newsletter
FILE SEGMENT: FULL

L11 ANSWER 8 OF 45 PHIN COPYRIGHT 2001 PJB

ACCESSION NUMBER: 2000:15210 PHIN
DOCUMENT NUMBER: C00677424
DATA ENTRY DATE: 29 Aug 2000
TITLE: Medicare's changing coverage policy creates uncertainty
SOURCE: Clinica (2000) No. 923 p6
DOCUMENT TYPE: Newsletter
FILE SEGMENT: FULL

L11 ANSWER 9 OF 45 USPATFULL

ACCESSION NUMBER: 2000:132994 USPATFULL
TITLE: Apparatus and method to monitor photodynamic therapy
(PDT)
INVENTOR(S): Zeng, Haishan, 11786 85B Avenue, Delta, B. C., Canada
V4C 2W2
Lui, Harvey, 3415 West 11th Avenue, Vancouver, B. C.,
Canada V6R 2K1
MacAulay, Calum, 5791 Prince Albert Street, Vancouver,
B. C., Canada V5W 3E1
Palcic, Branko, 3758 Quesnel Drive, Vancouver, B. C.,
Canada V6L 2W8
McLean, David I., 1246 West 26th Avenue, Vancouver, B.
C., Canada V6H 2A9

	NUMBER	DATE
PATENT INFORMATION:	US 6128525	20001003
APPLICATION INFO.:	US 1997-901999	19970729 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Lateef, Marvin M.	
ASSISTANT EXAMINER:	Imam, Ali M.	
LEGAL REPRESENTATIVE:	Fulwider Patton Lee & Utecht, LLP	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	454	

AB A method and apparatus for controlling the dosimetry of a photodynamic therapy that involves exposing a site to be treated to treatment light in order to generate toxic products at the site and other photoproducts.

Often a photosensitizer drug is administered to the patient prior to treatment or the therapy relies on the presence of endogenous photosensitizers. The method comprises the steps of selecting a photoproduct having an identifying characteristic, which can be a fluorescence peak, and monitoring the photoproduct using the identifying

characteristic (e.g. fluorescence) to determine the level of the photoproduct being generated. The photodynamic therapy is then terminated when the photoproduct being monitored reaches a predetermined level. The method allows for safe treatment of a site using photodynamic therapy and ensures that overexposure to treatment light leading to damage of normal tissue or underexposure leading to ineffective treatment of the lesion does not occur. Apparatus for automatically carrying out the method is also provided.

L11 ANSWER 10 OF 45 USPATFULL

ACCESSION NUMBER: 2000:121505 USPATFULL
TITLE: Model and method for angiogenesis inhibition
INVENTOR(S): Margaron, Philippe Maria Clotaire, Burnaby, Canada
Leong, Simon, Burnaby, Canada
Levy, Julia G., Vancouver, Canada
Richter, Anna M., Vancouver, Canada
PATENT ASSIGNEE(S): QLT, Inc., Japan (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6117862	20000912
APPLICATION INFO.:	US 1998-169735	<u>19981009</u> (9)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Jones, Dwayne C.	
LEGAL REPRESENTATIVE:	Morrison & Foerster	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	488	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a method to inhibit the formation of neovasculature while maintaining viability of the underlying tissue by subjecting a subject in which angiogenesis is to be inhibited to sublethal photodynamic therapy. The invention also provides a model for assessing sublethal PDT protocols to inhibit angiogenesis in particular target tissues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 11-20

L11 ANSWER 11 OF 45 USPATFULL

AN 2000:109830 USPATFULL
TI Green porphyrins as immunomodulators
IN Chan, Agnes H., Port Moody, Canada
Hunt, David W. C., White Rock, Canada
Levy, Julia G., Vancouver, Canada
Obochi, Modestus O. K., Vancouver, Canada
Richter, Anna M., Vancouver, Canada
Simkin, Guillermo O., North Vancouver, Canada
PA QLT PhotoTherapeutics, Inc., Canada (non-U.S. corporation)
The University of British Columbia, Canada (non-U.S. corporation)
PI US 6107325 20000822
AI US 1998-80666 19980518 (9)
RLI Continuation-in-part of Ser. No. US 1997-856921, filed on 16 May 1997
which is a continuation-in-part of Ser. No. US 1995-374158, filed on 17

Jan 1995, now patented, Pat. No. US 5789433
DT Utility
LN.CNT 1032
INCL INCLM: 514/410.000
NCL NCLM: 514/410.000
IC [7]
ICM: A01N043-38
EXF 514/410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 45 USPATFULL
AN 2000:102323 USPATFULL
TI Photodynamic therapy in selective cell inactivation in blood and
treating immune dysfunction diseases
IN Levy, Julia G., Vancouver, Canada
North, Janice, Vancouver, Canada
PA QLT Inc., Canada (non-U.S. corporation)
The University of British Columbia, Canada (non-U.S. corporation)
PI US 6100290 20000808
AI ~~US 1998-152993~~ 19980914 (9)
RLI Continuation of Ser. No. US 1994-309509, filed on 22 Sep 1994, now
patented, Pat. No. US 5807881, issued on 15 Sep 1998 which is a
continuation-in-part of Ser. No. US 1992-889707, filed on 27 May 1992,
now patented, Pat. No. US 5776966, issued on 7 Jul 1998
DT Utility
LN.CNT 967
INCL INCLM: 514/410.000
INCLS: 514/885.000; 514/908.000; 604/004.000; 604/005.000
NCL NCLM: 514/410.000
NCLS: 514/885.000; 514/908.000; 604/004.010
IC [7]
ICM: A61K031-40
EXF 514/410; 514/885; 514/908; 604/4; 604/5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 45 USPATFULL
AN 2000:98460 USPATFULL
TI Green porphyrins as immunomodulators
IN Chan, Agnes H., Port Moody, Canada
Hunt, David W. C., White Rock, Canada
Levy, Julia G., Vancouver, Canada
Obochi, Modestus O. K., Vancouver, Canada
Richter, Anna M., Vancouver, Canada
Simkin, Guillermo O., Vancouver, Canada
PA QLT PhotoTherapeutics, Inc., Canada (non-U.S. corporation)
The University of British Columbia, Canada (non-U.S. corporation)
PI US 6096776 20000801
AI US 1998-164374 19981001 (9)
RLI Continuation-in-part of Ser. No. US 1997-856921, filed on 16 May 1997,
now patented, Pat. No. US 6008241 which is a continuation-in-part of
Ser. No. US 1995-374158, filed on 17 Jan 1995, now patented, Pat. No.
US 5789433
DT Utility
LN.CNT 607
INCL INCLM: 514/410.000
NCL NCLM: 514/410.000
IC [7]
ICM: A61K031-40
EXF 514/410

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 45 USPATFULL
AN 2000:80885 USPATFULL
TI Taxanes
IN Swindell, Charles S., Merion, PA, United States
Shashoua, Victor E., Brookline, MA, United States
Bradley, Matthews O., Laytonsville, MD, United States
Webb, Nigel L., Bryn Mawr, PA, United States
PA Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)
PI US 6080877 20000627
AI US 1997-868476 19970603 (8)
RLI Continuation of Ser. No. US 1996-651429, filed on 22 May 1996, now abandoned
DT Utility
LN.CNT 1034
INCL INCLM: 549/510.000
INCLS: 549/511.000; 514/449.000
NCL NCLM: 549/510.000
NCLS: 549/511.000
IC [7]
ICM: C07D305-14
ICS: A61K031-335
EXF 549/510; 549/511; 514/449
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 45 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 2000-594142 [56] WPIDS
DNC C2000-177376
TI Enhancing destruction of target cells such as smooth muscle cells or tumor
cells for cancer therapy, involves using photodynamic therapy in combination with apoptosis-inducing factors.
DC B02 B04
IN CARTHY, C M; GRANVILLE, D J; HUNT, D W C
PA (QLTP-N) QLT PHOTOTHERAPEUTICS INC
CYC 90
PI WO 2000051638 A1 20000908 (200056)* EN 64p A61K041-00
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ TZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2000027899 A 20000921 (200065) A61K041-00
ADT WO 2000051638 A1 WO 2000-CA200 20000225; AU 2000027899 A AU 2000-27899
20000225
FDT AU 2000027899 A Based on WO 200051638
PRAI US 1999-121770 , 19990226
IC ICM A61K041-00

L11 ANSWER 16 OF 45 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
AN 2000437509 EMBASE
TI [Limited macular translocation].
BEGRENZTE TRANSLOKATION DER MAKULA BEI SUBFOVEALER CHOROIDALER
NEOVASKULARISATION.
AU Wiedemann P.; Faude F.; Jochmann C.; Sterker I.; Wolf S.; Zeumer C.
CS P. Wiedemann, Klinik Poliklinik für Augenheilkunde, Liebigstrasse 10-14,
D-04103 Leipzig, Germany
SO Spektrum der Augenheilkunde, (2000) 14/5 (254-258).

Refs: 18
ISSN: 0930-4282 CODEN: SPAUET
CY Austria
DT Journal; Article
FS 012 Ophthalmology
LA German
SL English; German

L11 ANSWER 17 OF 45 MEDLINE DUPLICATE 1
AN 2001048490 MEDLINE
DN 20386242 PubMed ID: 10933111
TI Benzoporphyrin derivative monacid ring A (**Verteporfin**) alone has
no inhibitory effect on **intimal hyperplasia**: in vitro
and in vivo results.
AU Turnbull R G; Chen J C; Labow R S; Margaron P; Hsiang Y N
CS University of British Columbia, Vancouver, Canada.
SO JOURNAL OF INVESTIGATIVE SURGERY, (2000 May-Jun) 13 (3) 153-9.
Journal code: AZA. ISSN: 0894-1939.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200012
ED Entered STN: 20010322
Last Updated on STN: 20010322
Entered PubMed: 20001121
Entered Medline: 20001214

L11 ANSWER 18 OF 45 PROMT COPYRIGHT 2001 Gale Group

ACCESSION NUMBER: 1999:208043 PROMT
TITLE: Best PIPELINES.
AUTHOR(S): Engel, Styli
SOURCE: Med Ad News, (March 1999) Vol. 18, No. 3, pp. 1(1).
ISSN: 0745-0907.
PUBLISHER: Engel Communications, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 41331
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L11 ANSWER 19 OF 45 PHIN COPYRIGHT 2001 PJB

AN 1999:3225 PHIN
DN S00609484
DED 29 Jan 1999
TI Pharmacia and Upjohn ups investment in Miravant AMD (age-related macular
degeneration) drug
SO Scrip (1999) No. 2407 p10
DT Newsletter
FS FULL

L11 ANSWER 20 OF 45 PHIN COPYRIGHT 2001 PJB

AN 2000:244 PHIN
DN S00646196
DED 3 Dec 1999
TI Novartis acquires Destiny's PDT (photodynamic therapy)
SO Scrip (1999) No. 2495 p8
DT Newsletter

FS FULL

=> d 21-30

L11 ANSWER 21 OF 45 USPATFULL
AN 1999:170633 USPATFULL
TI Green porphyrins as immunomodulators
IN Chan, Agnes H., Fort Moody, Canada
Hunt, David W. C., White Rock, Canada
Levy, Julia G., Vancouver, Canada
Obochi, Modestus O. K., Vancouver, Canada
Richter, Anna M., Vancouver, Canada
Simkin, Guillermo O., North Vancouver, Canada
PA QLT PhotoTherapeutics, Inc., Vancouver, Canada (non-U.S. corporation)
PI US 6008241 19991228
AI US 1997-856921 19970516 (8)
RLI Continuation-in-part of Ser. No. US 1995-374158, filed on 17 Jan 1995,
now patented, Pat. No. US 5789433
DT Utility
LN.CNT 966
INCL INCLM: 514/410.000
NCL NCLM: 514/410.000
IC [6]
ICM: A61K031-40
EXF 514/410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 22 OF 45 USPATFULL
AN 1999:110319 USPATFULL
TI Benzophenothiazine and benzoporphyrin dye combination photodynamic
therapy of tumors
IN Cincotta, Anthony H., Charlestown, MA, United States
Cincotta, Louis, Andover, MA, United States
Hasan, Tayyaba, Arlington, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S.
corporation)
Rowland Institute for Science, Cambridge, MA, United States (U.S.
corporation)
PI US 5952329 19990914
AI US 1997-787665 19970123 (8)
DT Utility
LN.CNT 707
INCL INCLM: 514/224.500
INCLS: 514/410.000
NCL NCLM: 514/224.500
NCLS: 514/410.000
IC [6]
ICM: A61K031-54
ICS: A61K031-40
EXF 514/224.5; 514/410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 23 OF 45 USPATFULL
AN 1999:99682 USPATFULL
TI Photodynamic therapy for the treatment of osteoarthritis
IN Trauner, Kenneth, Sacramento, CA, United States
Hasan, Tayyaba, Arlington, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S.
corporation)

PI US 5942534 19990824
AI US 1997-948623 19971010 (8)
PRAI US 1996-28198 19961010 (60)
DT Utility
LN.CNT 864
INCL INCLM: 514/410.000
INCLS: 514/561.000; 514/429.000; 514/825.000
NCL NCLM: 514/410.000
NCLS: 514/429.000; 514/561.000; 514/825.000
IC [6]
ICM: A01N043-38
EXF 514/561; 514/825; 514/410; 514/429
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 24 OF 45 USPATFULL
AN 1999:75671 USPATFULL
TI Taxane compounds and compositions
IN Bradley, Matthews O., Laytonville, MD, United States
Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
PA Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)
PI US 5919815 19990706
AI US 1996-653951 19960522 (8)
DT Utility
LN.CNT 940
INCL INCLM: 514/449.000
INCLS: 549/510.000
NCL NCLM: 514/449.000
NCLS: 549/510.000
IC [6]
ICM: A61K031-335
EXF 549/510; 514/449
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 25 OF 45 USPATFULL
AN 1999:33242 USPATFULL
TI Method to prevent transplant rejection
IN Levy, Julia G., Vancouver, Canada
Obochi, Modestus O. K., Vancouver, Canada
PA QLT Phototherapeutics, Inc., Vancouver, Canada (non-U.S. corporation)
PI US 5882328 19990316
AI US 1996-759318 19961202 (8)
RLI Continuation-in-part of Ser. No. US 1995-371707, filed on 13 Jan 1995,
now abandoned
DT Utility
LN.CNT 1461
INCL INCLM: 604/020.000
INCLS: 604/049.000; 424/810.000; 128/898.000
NCL NCLM: 604/020.000
NCLS: 128/898.000; 424/810.000; 604/500.000
IC [6]
ICM: A61N001-30
ICS: I61M031-00
EXF 604/19; 604/20; 604/48; 604/49; 514/885; 530/388.7; 530/388.73;
530/388.75; 530/388.8; 530/388.85; 424/810; 424/140.1; 128/898
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 26 OF 45 CAPLUS COPYRIGHT 2001 ACS
AN 1999:682214 CAPLUS

DN 132:10414
TI Significance of dosimetry in photodynamic therapy of injured arteries:
classification of biological responses
AU Adili, Farzin; Van Eps, Randolph G. Statius; LaMuraglia, Glenn M.
CS Division of Vascular Surgery and the Wellman Laboratories of
Photomedicine, Harvard Medical School, Massachusetts General Hospital,
Boston, MA, 02114, USA
SO Photochem. Photobiol. (1999), 70(4), 663-668
CODEN: PHCBAP; ISSN: 0031-8655
PB American Society for Photobiology
DT Journal
LA English
RE.CNT 29
RE

(4) Dubbelman, T; Photodynamic Therapy Basic Principles and Clinical
Applications 1992, P37 CAPLUS
(5) Eton, D; Arch Surg 1995, V130, P1098 CAPLUS
(8) Grant, W; Br J Cancer 1994, V70, P72 CAPLUS
(9) Grant, W; Laryngoscope 1995, V105, P867 CAPLUS
(10) Henderson, B; Photochem Photobiol 1992, V55, P145 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 27 OF 45 PROMT COPYRIGHT 2001 Gale Group

ACCESSION NUMBER: 1998:222577 PROMT
TITLE: ATTENTION BUSINESS EDITORS:
SOURCE: PR Newswire, (30 Apr 1998) pp. 0430VA002.
LANGUAGE: English
WORD COUNT: 1352
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L11 ANSWER 28 OF 45 PROMT COPYRIGHT 2001 Gale Group

ACCESSION NUMBER: 1998:222488 PROMT
TITLE: QLT Announces Strategic Alliance With Bard To Develop
System For **Restenosis**
SOURCE: PR Newswire, (30 Apr 1998) pp. 0430LNTH001.
LANGUAGE: English
WORD COUNT: 765
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L11 ANSWER 29 OF 45 USPATFULL

AN 1998:138935 USPATFULL
TI Methods to treat arterial plaque
IN Kelly, Barbara, Vancouver, Canada
Levy, Julia, Vancouver, Canada
Margaron, Philippe Maria Clotaire, Vancouver, Canada
PA QLT Phototherapeutics, Inc., Vancouver, Canada (non-U.S. corporation)
PI US 5834503 19981110
AI US 1996-66389Q 19960614 (8)
DT Utility
LN.CNT 671
INCL INCLM: 514/410.000
INCLS: 514/824.000
NCL NCLM: 514/410.000
NCLS: 514/824.000
IC [6]
ICM: A61K031-40
EXF 514/410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 30 OF 45 USPATFULL
 AN 1998:111961 USPATFULL
 TI Method for selectively reducing activated leukocyte cell population
 IN Leong, Simon, Vancouver, Canada
 Chan, Agnes How-Ching, Port Moody, Canada
 Hunt, David William Carey, White Rock, Canada
 Levy, Julia, Vancouver, Canada
 Renke, Martin, Burnaby, Canada
 PA Quadra Logic Technologies, Inc., Vancouver, Canada (non-U.S.
 corporation)
 University of British Columbia, Vancouver, Canada (non-U.S.
 corporation)
 PI US 5807881 19980915
 AI US 1994-309509 19940922 (8)
 RLI Continuation-in-part of Ser. No. US 1992-889707, filed on 27 May 1992
 DT Utility
 LN.CNT 1016
 INCL INCLM: 514/410.000
 INCLS: 604/004.000; 604/005.000; 514/885.000; 514/908.000
 NCL NCLM: 514/410.000
 NCLS: 514/885.000; 514/908.000; 604/006.080
 IC [6]
 ICM: A61K031-40
 EXF 514/410; 604/4; 604/5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 31-45

L11 ANSWER 31 OF 45 USPATFULL
 AN 1998:98932 USPATFULL
 TI DHA-pharmaceutical agent conjugates of taxanes
 IN Shashoua, Victor E., Brookline, MA, United States
 Swindell, Charles S., Merion, PA, United States
 Webb, Nigel L., Bryn Mawr, PA, United States
 Bradley, Matthews O., Laytonsville, MD, United States
 PA Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)
 PI US 5795909 19980818
 AI US 1996-651312 19960522 (8)
 DT Utility
 LN.CNT 2451
 INCL INCLM: 514/449.000
 INCLS: 514/549.000
 NCL NCLM: 514/449.000
 NCLS: 514/549.000
 IC [6]
 ICM: A61K031-335
 ICS: A61K031-22
 EXF 514/449; 514/549
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 32 OF 45 MEDLINE
 AN 1999103397 MEDLINE
 DN 99103397 PubMed ID: 9888322
 TI Photodynamic therapy with local photosensitizer delivery inhibits
 experimental **intimal hyperplasia**.
 AU Adili F; Statius van Eps R G; Flotte T J; LaMuraglia G M
 CS Division of Vascular Surgery, Massachusetts General Hospital and Harvard
 Medical School, Boston 02114, USA.

DUPLICATE 2

NC HL02583 (NHLBI)
 SO LASERS IN SURGERY AND MEDICINE, (1998) 23 (5) 263-73.
 Journal code: L1X; 8007168. ISSN: 0196-8092.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199903
 ED Entered STN: 19990402
 Last Updated on STN: 19990402
 Entered Medline: 19990322

L11 ANSWER 33 OF 45 CAPLUS COPYRIGHT 2001 ACS
 AN 1997:319963 CAPLUS
 DN 126:327524
 TI Delivery of benzoporphyrin derivative, a photosensitizer, into
 atherosclerotic plaque of Watanabe heritable hyperlipidemic rabbits and
 balloon-injured New Zealand rabbits
 AU Allison, B. A.; Crespo, M. T.; Jain, A. K.; Richter, A. M.; Hsiang, Y.
 N.;
 Levy, J. G.
 CS Department of Surgery, University of British Columbia, Vancouver, BC, V6T
 2B5, Can.
 SO Photochem. Photobiol. (1997), 65(5), 877-883
 CODEN: PHCBAP; ISSN: 0031-8655
 PB American Society for Photobiology
 DT Journal
 LA English

L11 ANSWER 34 OF 45 DRUGU COPYRIGHT 2001 DERWENT INFORMATION LTD
 AN 1996-48628 DRUGU P
 TI Tin ethyl etiopurpurin significantly inhibits vascular smooth muscle
 cell
 proliferation in vivo.
 AU Coats W D Jr; Currier J W; Mejias Y; Narciso H L; Faxon D P
 CS Univ.Southern-California
 LO Los Angeles, Cal., USA
 SO Biochem.Cell Biol. (74, No. 3, 325-31, 1996) 4 Fig. 23 Ref.
 CODEN: BCBIEQ ISSN: 0829-8211
 AV The Department of Medicine, Division of Cardiology, University of
 Southern California School of Medicine, 1355 San Pablo Street, Los
 Angeles, CA 90033, U.S.A.
 LA English
 DT Journal
 FA AB; LA; CT
 FS Literature

L11 ANSWER 35 OF 45 CAPLUS COPYRIGHT 2001 ACS
 AN 1996:434564 CAPLUS
 DN 125:136570
 TI Effects of benzoporphyrin derivative monoacid on balloon injured arteries
 in a swine model of **restenosis**
 AU Vincent, G. Michael; Fox, Jolene; Johnson, Suzanne; Maragon, Phillipe
 CS LDS Hospital, Salt Lake City, UT, USA
 SO Proc. SPIE-Int. Soc. Opt. Eng. (1996), 2671(Lasers in Surgery: Advanced
 Characterization, Therapeutics, and Systems VI), 72-77
 CODEN: PSISDG; ISSN: 0277-786X
 DT Journal
 LA English

L11 ANSWER 36 OF 45 PASCAL COPYRIGHT 2001 INIST-CNRS. ALL RIGHTS RESERVED.
 AN 1997-0009011 PASCAL
 CP Copyright .COPYRGT. 1996 INIST-CNRS. All rights reserved.
 TIEN Effects of benzoporphyrin derivative monoacid on balloon injured
 arteries
 in a swine model of **restenosis** : Diagnostic and therapeutic
 cardiovascular intervention VI
 Lasers in surgery : advanced characterization, therapeutics, and systems
 VI : San Jose CA, 27-30 Janaury 1996
 AU VINCENT G. M.; FOX J.; JOHNSON S.; MARAGON P.
 ANDERSON R. Rox (ed.)
 CS LDS Hospital/University of Utah School of Medicine, Salt Lake City, UT,
 United States; QLT Phototherapeutics Inc., Vancouver, B.C., Canada
 International Society for Optical Engineering, Bellingham WA, United
 States (patr.)
 SO SPIE proceedings series, (1996), 2671, 72-77, 18 refs.
 Conference: 6 Lasers in surgery : advanced characterization,
 therapeutics, and systems. Conference, San Jose CA (United States), 27
 Jan 1996
 ISSN: 1017-2653
 DT Journal; Conference
 BL Analytic
 CY United States
 LA English
 AV INIST-21760, 354000064004780100

L11 ANSWER 37 OF 45 USPATFULL
 AN 95:50186 USPATFULL
 TI Method to inhibit **restenosis**
 IN Vincent, G. Michael, Salt Lake City, UT, United States
 Logan, Patricia M., Vancouver, Canada
 PA Quadra Logic Technologies, Inc., Vancouver, Canada (non-U.S.
 corporation)
 PI US 5422362 19950606
 AI US 1993-99210 19930729 (8)
 DT Utility
 LN.CNT 618
 INCL INCLM: 514/410.000
 NCL NCLM: 514/410.000
 IC [6]
 ICM: A61K031-40
 EXF 514/410
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 38 OF 45 CAPLUS COPYRIGHT 2001 ACS
 AN 1995:446841 CAPLUS
 DN 122:178400
 TI Green porphyrins for inhibition of **restenosis**
 IN Vincent, G. Michael; Logan, Patricia M.
 PA Quadra Logic Technologies, Inc., Can.
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9503797	A1	19950209	WO 1994-US8200	19940720
	W: AU, CA, CN, CZ, FI, JP, KR, NO, NZ, PL, RU, SK, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

US 5422362	A	19950606	US 1993-99210	19930729
CA 2168043	AA	19950209	CA 1994-2168043	19940720
AU 9474017	A1	19950228	AU 1994-74017	19940720
AU 684301	B2	19971211		
EP 711161	A1	19960515	EP 1994-923992	19940720

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,

SE

CN 1127991	A	19960731	CN 1994-192924	19940720
JP 09503998	T2	19970422	JP 1994-505883	19940720
ZA 9405657	A	19960129	ZA 1994-5657	19940729
NO 9600339	A	19960326	NO 1996-339	19960126

PRAI US 1993-99210 19930729

WO 1994-US8200 19940720

OS MARPAT 122:178400

L11 ANSWER 39 OF 45 SCISEARCH COPYRIGHT 2001 ISI (R)

AN 95:746273 SCISEARCH

GA The Genuine Article (R) Number: TB169

TI ASSESSMENT OF THE CYTOTOXICITY OF THE PHOTSENSITIZING DRUG BPD
VERTEPORFIN USING HUMAN VASCULAR SMOOTH-MUSCLE CELLS IN CULTURE

AU LABOW R S (Reprint); HIGGINSON L A J; IRVINE J; KEANEY M; MASTERS R G;
MARQUIS J F; MEEK E; MUSSIVAND T; WALLEY V M; LOGAN P; CHALY N; LOWRY M

CS UNIV OTTAWA, OTTAWA CIVIC HOSP, INST HEART, DIV CARDIOVASC DEVICES, 1053
CARLING AVE, OTTAWA, ON K1Y 4E9, CANADA (Reprint); QUADRA LOG TECHNOL,
VANCOUVER, BC, CANADA; CARLETON UNIV, DEPT BIOL, OTTAWA, ON K1S 5B6,
CANADA

CYA CANADA

SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, (NOV 1995) Vol. 26, No. 5, pp.
729-736.
ISSN: 0160-2446.

DT Article; Journal

FS LIFE; CLIN

LA ENGLISH

REC Reference Count: 36
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L11 ANSWER 40 OF 45 CAPLUS COPYRIGHT 2001 ACS

AN 1995:702859 CAPLUS

DN 123:164182

TI Local delivery of photosensitizing drugs in arteries: a novel approach to
photodynamic therapy for the prevention of **intimal**
hyperplasia

AU Adili, Farzin; van Eps, Randolph G. S.; LaMuraglia, Glenn M.

CS Harvard Medical School, Massachusetts General Hospital, Boston, MA,
02114,
USA

SO Proc. SPIE-Int. Soc. Opt. Eng. (1995), 2395, 402-8
CODEN: PSISDG; ISSN: 0277-786X

DT Journal

LA English

L11 ANSWER 41 OF 45 DRUGNL COPYRIGHT 2001 IMSWORLD

ACCESSION NUMBER: 94:1182 DRUGNL

TITLE: **Verteporfin** Effective in Psoriasis Clinicals

SOURCE: R&D Focus Drug News (31 Oct 1994).

WORD COUNT: 207

L11 ANSWER 42 OF 45 MEDLINE

AN 95084221 MEDLINE

DUPLICATE 3

DN 95084221 PubMed ID: 7992105
TI Photosensitizers in photodynamic therapy.
AU Levy J G
CS Quadra Logic Technologies, Inc, Vancouver, British Columbia, Canada.
SO SEMINARS IN ONCOLOGY, (1994 Dec) 21 (6 Suppl 15) 4-10.
Journal code: UN5; 0420432. ISSN: 0093-7754.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199501
ED Entered STN: 19950124
Last Updated on STN: 19980206
Entered Medline: 19950112

L11 ANSWER 43 OF 45 ADISINSIGHT COPYRIGHT 2001 (ADIS)

ACCESSION NUMBER: 1998:5242 ADISINSIGHT

SOURCE: Adis R&D Insight

DOCUMENT NO: 005843

CHANGE DATE: May 9, 2001

GENERIC NAME: **Verteporfin**

SYNONYM: BPD; BPD-MA; Benzoporphyrin derivative monoacid ring A;
CL 315555; CL 315585; CL 318952; Everteporfine;

Visudyne

CHEMICAL NAME: 50:50 mixture of: (+-)-trans-3,4-dicarboxy-
4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-
23H,25H-benzo(b)porphine- 9,13-dipropionic acid,
3,4,9-trimethyl ester and (+-)-trans-3,4-dicarboxy-
4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-
23H,25H-benzo(b)porphine-9,13-dipropionic acid,
3,4,13-trimethyl ester.


MOLECULAR FORMULA: C41 H42 N4 O8

CAS REGISTRY NO.: 129497-78-5

STRUCTURE:

CM 1

Relative stereochemistry.
Double bond geometry unknown.



CM 2

H₃C-OH

EPHMRA ATC CODE: C6A Other Cardiovascular Products; D5A Topical
Antipsoriasis and Similar Products; L1X9 All other
cytostatics; L3 Immunostimulating Agents; M1A
Anti-Rheumatics, Non-Steroidal; S1X Other
Ophthalmologicals
WHO ATC CODE: C Cardiovascular System; D05A-X Other antipsoriatics
for topical use; L01X Other Antineoplastic Agents; L03
Immunostimulants; M01A Antiinflammatory and
Antirheumatic Products, Non-steroids; S01X Other
Ophthalmologicals
HIGHEST DEV. PHASE: Launched
COMPANY INFORMATION
ORIGINATOR: Nonindustrial source (Canada)
PARENT: Nonindustrial source
LICENSEE: Medtronic AVE; Novartis Ophthalmics; QLT
OTHER: Coherent; Nippon Fine Chemical; Parkedale
Pharmaceuticals; Raylo
WORD COUNT: 2819

L11 ANSWER 44 OF 45 DRUGUPDATES COPYRIGHT 2001 IMSWORLD

ACCESSION NUMBER: 93:3852 DRUGUPDATES
SOURCE: R&D Focus, (2 Apr 2001)
GENERIC NAME: **verteporfin**; benzoporphyrin derivative; BPD-MA
REFERENCE: USAN
LABORATORY NAME: CL 318952; BPDR
TRADE NAME: VISUDYNE
CHEMICAL NAME: trans-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-
4a,8,14,19-tetr amethyl-23H,25H-benzo[b]porphine-9,13-
dipropanoic acid monomethyl ester
CAS REGISTRY NO.: **129497-78-5**
STRUCTURE:

CM 1

Relative stereochemistry.
Double bond geometry unknown.



L11 ANSWER 45 OF 45 PHAR COPYRIGHT 2001 PJB
AN 1589 PHAR
DN 013031
CN **verteporfin**
CN BPD
CN BPD-MA

CN benzoporphyrin derivative
 CN Chlorin
 CN CL-315555+CL-315585
 CN CL-318952
 CN Visudyne
 CN 23H,25H-Benzo(b)porphine-9,13-dipropionic
 acid,18-ethenyl-4,4a-dihydro-3,4-
 bis(methoxycarbonyl)-4a,8,14,19-tetramethyl -,monomethyl ester, trans-
 (CAS)
 RN 129497-78-5
 STA Active

CO

Type	Company Name (Country)	Development Status
Originator	QLT (Canada)	Launched
Licensee	Novartis Ophthalmics (Switzerland)	Launched
Licensee	Sanofi-Synthelabo (France)	Phase II Clinical Trial
Licensee	Beaufour-Ipsen (France)	Phase II Clinical Trial

SO Pharmaprojects. PJB Publications Ltd., Richmond, Surrey, UK
 TX QLT has developed **verteporfin**, a light-activated benzoporphyrin derivative (BPD), as a photodynamic therapy (licensed from the University of British Columbia, Canada). A photochemical dye is injected iv and localizes to areas of new blood vessels. Non-thermal laser irradiation is then used to produce vascular occlusion (Br J Ophthalmol, 1998, 82, 472).

Marketing

It is launched in Switzerland (1999), Germany, the UK and the US (2000) (Chem Brit, Apr, 2000, 6; Scrip Daily Online, 9 Nov 2000, S00686884) for the treatment of wet age-related macular degeneration (AMD) in patients with predominantly classic subfoveal choroidal neovascularization (CNV) (Press releases, Ciba Vision, 16 Dec 1999 and QLT, 12 Apr 2000). It is registered in 31 countries (as of Feb 2001) including Australia, Canada and the EU for the treatment of AMD (Press releases, Ciba Vision, 1 Jun and 3 Oct 2000 and Novartis Ophthalmics, 5 Feb 2001). It is also approved in the EU for the treatment of CNV secondary to pathologic myopia (Press release, Novartis Ophthalmics, 23 Mar 2001). It is awaiting registration in Argentina, Brazil, Iceland, India, New Zealand (accelerated review status) and Norway (Scrip Daily Online, 14 Feb 2000; Press releases, Ciba Vision, 18 Aug and 28 Mar 2000). An agreement has been signed with Novartis Ophthalmics (previously Ciba Vision Ophthalmics) for use in eye diseases, such as AMD, glaucoma and secondary cataracts (preclinical), CNV, intraocular tumours and diabetic retinopathy (Company communications, Ciba Vision, Feb 1995 and QLT, Feb 1995; Scrip, 1995, 2083, 11; Press release, QLT, Mar 1996). A filing for the treatment of eye diseases other than AMD has been submitted to the EMEA by QLT and Novartis Ophthalmics (Press release, Ciba Vision, 3 Oct 2000). A US supplemental filing for pathologic myopia has been granted priority review status (approvable letter received; approval expected in mid-2001) (Company Web Page, Novartis, 16 Jan 2001; Press release, Novartis Ophthalmics, 5 Feb 2001). Sanofi-Synthelabo holds rights to development for cutaneous cancers (Phase II trials) and psoriasis (Scrip, 1996, 2146, 11). It is being developed with

Beaufour-Ipsen for oncology (Company communication, Dec 1997). The Baylor Research Institute, Dallas, TX, the US, has an agreement for use in viral inactivation and blood-borne disease (Press release, QLT, Aug 1993). QLT has reacquired worldwide marketing rights from American Cyanamid (American Home Products) (Press release, QLT, Mar 1994). A licence to Novartis to co-develop and market **verteporfin** for cancer and psoriasis (US and Canadian Phase I/II trials with topical **verteporfin** were carried out) has been discontinued (Scrip, 1994, 1934, 9 and 1981, 23; Press release, QLT, Nov 1994; Direct communication, Novartis, 13 Mar 1999).

Clinical

In a 24mth, pivotal, randomized, double-blind study (TAP) in 609 AMD patients at 22 centres in N America and Europe, vision was stable or improved at 12mth follow-up, in 67% of patients cf 39% of placebo recipients. **Verteporfin**-treated patients were 72% more likely to retain their vision cf placebo. Withdrawal due to adverse events was <3% (Press release, Ciba Vision, 11 Aug 1999). At 24mth follow-up, of the 242 patients with classic CNV, 59.1% of those treated lost <3 lines of vision cf 31.3% on placebo, and 13% of **verteporfin**-treated patients experienced an improvement in vision. Average number of treatments required decreased from 3.4 to 2.1 in the 2nd 12mth. It was safe and well tolerated. An open-label 24mth study (TAP extension) is underway. In a multicentre, randomized, placebo-controlled Phase IIIb study (VIP) in 120 patients with CNV due to pathologic myopia, 86.4% of **verteporfin**-treated patients lost <3 lines of vision cf 66.7% on placebo, and treated patients showed significant improvements in contrast sensitivity, lesion size and amount of leakage. In an additional multicentre, randomized, placebo-controlled Phase IIIb trial in 339 AMD patients with a different pattern of CNV, not eligible for the TAP trial, **verteporfin** did not produce significant benefit, with 49.3% of treated patients losing <3 lines of vision cf 45.6% on placebo (Press release, Ciba Vision and QLT, 28 Mar 2000). In a Phase IIIb clinical trial in AMD patients with occult subfoveal CNS, **verteporfin** was efficacious (Scrip Daily Online, 8 Feb 2001, S00696576). It was in Phase III trials as an immunosuppressant (bone marrow purging) and in Phase I/II as an immunological anti-HIV agent (Company communications, QLT, Feb 1993 and Dec 1995). In a Phase II study in 54 patients with non-melanoma skin cancer in the US and Canada, **verteporfin** produced CRs in 98% of tumours 6mth after treatment at the highest light dose (Press release, QLT, 31 Oct 2000). In case studies of patients with macular degeneration, drug treatment resulted in stabilization of vision and reduction in vision distortion (Company communication, QLT, Nov 1995). In 61 patients with wet AMD, partial or complete closure of the diseased blood vessels was demonstrated in all lesions post-treatment. In the majority of patients, selective closure was achieved and blood vessel leakage was significantly reduced, while mean visual acuity remained stable over a 3mth follow-up period (Press release, QLT, Apr 1996). In a Phase I trial in 19 psoriasis patients, 5 had >35% reduction in total PASI (Psoriasis Area and Severity Index) scores after 9wk, with 2 patients experiencing 77 and 61% reduction, respectively. The most common side-effect (21%) was mild-to-moderate pruritus. BPD is in Phase I trials for gynaecological infections (Company communications, QLT, Jan 1993 and Mar 1995).

Preclinical

Verteporfin is also under investigation for atherosclerosis, multiple sclerosis (both preclinical),

restenosis, cervical dysplasia and in Japan for AMD (Company communications, QLT, Jan 1993 and Mar 1995; Scrip, 1996, 2146, 11).
Updated by AW on 23/3/2001.

Additional References Arch Ophthalmol, 1999, 117, 1329.

DSTA World: Launched
Argentina: Pre-registration
Australia: Registered
Austria: Registered
Belgium: Registered
Brazil: Pre-registration
Canada: Registered
Denmark: Registered
France: Registered
Germany, Federal Republic of: Launched 2000
Greece: Registered
Ireland: Registered
Italy: Registered
Japan: Preclinical
Netherlands: Registered
Portugal: Registered
Spain: Registered
Sweden: Registered
Switzerland: Launched 1999
United Kingdom: Launched 2000
United States: Launched 2000

CC S1Z Ophthalmological
I5 Immunosuppressant
I1A Immunostimulant, anti-AIDS
K5A Radio-chemosensitizer
K6Z Anticancer, other
D5A Antipsoriasis

CT Indication: Macular degeneration; Transplant rejection, bone marrow;
Infection, HIV/AIDS; Cancer, skin, general; Psoriasis; Infection,
gynaecological

ORGM CH-SY (Chemical synthesis, synthetic)

RTE P-IV (Parenteral, intravenous)

RDAT 19911215 RNTE ##Status changed Phase I Clinical Trial
19920315 ##Status changed Phase II Clinical Trial
19930305 ##Status changed Phase III Clinical Trial
19940520 ##Licensee discontinued American Cyanamid
19940617 ##New Licensee Ciba Vision
19940708 ##New Licensee Ciba-Geigy
19950616 ##Change in Licensee Status Ciba Vision Ophthalmics, Phase
I Clinical Trial
19950623 ##Change in Licensee Status Ciba Vision, Phase I Clinical
Trial
19960426 ##Change in Licensee Status Ciba Vision Ophthalmics, Phase
II Clinical Trial
19960816 ##New Licensee Sanofi
19971219 ##New Licensee Beaufour Ipsen
19990319 ##Licensee discontinued Novartis
19990813 ##Registration submission The EU
20000114 ##First registration Switzerland, 19991216
20000421 ##Additional registration The US
20000526 ##First launch NAS, Switzerland, 19991231
20000526 ##Additional launch The US
20000616 ##Additional registration Canada
20000811 ##Additional registration The EU
20000818 ##Additional launch The UK

20001006 ##Additional registration Australia
 20001117 ##Additional launch Germany
 PHCD RAD-AG; Physiological, Biochemical, Radical formation agonist;
 Radical formation stimulant; Antineoplastic e.g. rubicins; Radical
 donator; P-B-RAD-AG.
 PHCD P; P-AG; P-B; P-B-AG; P-B-RAD; P-B-RAD-AG; B; B-AG; B-RAD; B-RAD-AG;
 RAD; RAD-AG.

LN


Therapy (CC) | Pharmacology (PHCD) | Status (DSTC)

=====	=====	=====
S1Z	RAD-AG	L
I5	RAD-AG	C3
I1A	RAD-AG	C2
K5A	RAD-AG	C2
K6Z	RAD-AG	C2
D5A	RAD-AG	C1

NRAT 6: Novelty Rating - Leading Compound
 MRAT 3: Market Rating - US\$ 2001-5000 million
 SRAT 4: Speed Rating - Faster than Average
 TRAT 13: Total Rating - Total Rating

CM 1

Relative stereochemistry.
 Double bond geometry unknown.



CM 2

H₃C-OH

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
127.75	164.48

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.59	-0.59

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 11:34:06 ON 17 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: May 11, 2001 (20010511/UP).